INTRICATE RELATIONSHIP OF GUT MICROBIOTA IN THE PATHOGENESIS OF PSORIASIS AND THE ROLE OF AYURVEDA IN ITS MANAGEMENT: A COMPREHENSIVE REVIEW Authors: Girhepunje KS , GUPTA V, SRIVASTAVA VK AND SINGH OP
ABSTRACT
The diverse ecosystem of different microbial colonies inhabiting in the human intestine are
known as gut microbiota. This gut microbiota regulates our immunity to prevent from pathogens
by maintaining the gut barrier permeability. Any change in the symbiotic co-existence of these
microbiota ecosystem is termed as ‘dysbiosis’ responsible for various autoimmune disorders.
Psoriasis is one of the autoimmune dermatological condition characterised by erythema and
epidermal hyperkeratosis which is influenced by dysbiosis. Dysbiosis leads to increased
permeability of gut barrier triggering the various immunological cascade events through
activation of T lymphocytes. This is the onset point of pathogenesis of psoriasis which later
involves various influencing factors like interleukin (IL)-22, IL-17, IL-6, interferons (IFNs),
tumor necrotising factors (TNF), etc. The widespread use of immunosuppressive drugs and
antibiotics for long term is not satisfactory as per overall health concern of psoriatic patients due
significant disrupting effects on gut flora. Thus, recent advanced studies are focusing on the
treatment modalities which will strengthen pre-established microbial ecosystem. Ayurveda is a traditional and holistic healthcare system that strongly believe in the managing overall health of
diseased person without disrupting existed ecosystem. Virechana (therapeutic purgation) is one
of the methods of internal bio purification documented in Ayurveda and it is being practised in
India for treating psoriasis for thousands of years. It has been witnessed for its significant clinical
efficacy in psoriasis and various autoimmune ailments. Present study emphasizes the attention
over virechana for further clinical researches and to explore the complexity of microbial system.
Keywords: Gut flora; Dysbiosis; Gut ecosystem; Immunity; Dermatosis; Virechana Publication date: 01/03/2022 https://ijbpas.com/pdf/2022/March/MS_IJBPAS_2022_5935.pdfDownload PDFhttps://doi.org/10.31032/IJBPAS/2022/11.3.5935